How to Appeal a Denied Rare Disease Claim: A 5-Step Guide

A denial for a rare disease claim feels devastating. But it's not the end. Health plans must give you a clear reason and a way to appeal. Rare diseases don't fit standard guidelines, so denials happen: lack of protocols, high costs, misclassification. The appeals process is your structured path to challenge it. Your odds go up when you're strategic, thorough, and use every legal right under ERISA and the ACA.

Step 1: Understand Why the Claim Was Denied

Before you appeal, get the exact reason. The insurer must send a formal denial letter (required by ERISA for employer plans, state law for individual plans). That letter should include:

• The specific reason(s): "not medically necessary," "experimental/investigational," "out-of-network," or "not a covered benefit"
• The plan provision or exclusion cited
• The appeals process and deadlines
• Instructions for how to submit additional info

For rare diseases, the most common denial reasons are "experimental/investigational" or "lack of medical necessity." FDA-approved treatments may not exist, or plan guidelines were written for common conditions. Your appeal must address those points.

Start by requesting the plan's full clinical criteria and the documents it relied on. ERISA gives participants a right to copies of records relevant to their claim, and knowing the exact standard the plan applied tells you what your appeal has to overcome.

Step 2: Gather Critical Supporting Evidence

Your appeal is only as strong as the evidence you provide. A generic doctor's letter isn't enough. Collect these:

• Detailed letter from your treating specialist explaining why the denied treatment is medically necessary for your case. Include peer-reviewed studies, case reports, or clinical trial data.
• Medical records showing disease progression, failed alternative treatments, and symptoms.
• Published literature on the treatment's efficacy for your condition, even small studies or case series.
• Support from patient advocacy organizations (like NORD and the EveryLife Foundation): they often provide appeal guidance, research summaries, and help connecting you to specialists.
• A second opinion from a rare disease specialist at an academic medical center (many have dedicated clinics).

If the denial says "lack of medical necessity" or "experimental," submit a formal "Medical Necessity Appeal" with a clinical rationale from an expert. Plans sometimes require a peer-to-peer review: a direct talk between your doctor and their medical director. That can overturn denials in real time.

Step 3: Follow the Formal Internal Appeals Process

Every health plan has multi-level internal appeals. You must exhaust these before external review. Here's how:

1. File the first-level appeal within the deadline (at least 180 days for employer plans under ERISA). Write a formal letter referencing the claim number, denial reason, and your evidence. Send it certified mail or via the online portal with a receipt.
2. If denied, file a second-level internal appeal if your plan offers one for high-cost or rare disease claims. You can request an expedited appeal if delay could seriously harm your health.
3. Request a peer-to-peer review before or during the appeal. This is often the most effective step for rare disease claims because your specialist can discuss your unique case directly with the plan's physician, bypassing an algorithm or non-specialist. Have your specialist prepare against the plan's written criteria before the call.

Keep a detailed log of every phone call, email, and letter. Note names, dates, and what was discussed. Always meet every deadline; missing one can forfeit your appeal rights.

Step 4: If Internal Appeals Are Denied, Seek External Review

If the internal process fails, you have the right to an independent external review. Under the ACA, most non-grandfathered plans must allow this. The external decision is binding on the plan; if it rules against you, you keep other remedies, such as filing a lawsuit under federal or state law. Steps:

• File a request with the plan or state insurance department (the denial letter explains how). You have four months (about 120 days) from the final internal denial.
• Submit your case with all evidence: medical records, specialist letters, research.
• The external reviewer uses independent medical experts who evaluate against generally accepted standards of medical practice, not just the plan's guidelines.

External reviewers apply generally accepted clinical standards rather than the plan's own criteria, so off-label or novel treatments backed by credible evidence get a real look. That helps rare disease cases where the only option sits outside standard guidelines.

Fully insured plans usually go through a state external review program run through your state's insurance department. Self-insured plans go through a federal process. Your denial letter must explain which route applies. If a delay would put your health at risk, request an expedited external review.

Step 5: Elevate to Legal and Regulatory Options

If external review fails, you still have options:

• File a complaint with the Employee Benefits Security Administration (EBSA) if your plan is ERISA-governed. Its benefit advisors can help resolve disputes and enforce ERISA's claims rules.
• Hire an attorney specializing in ERISA, health insurance, or rare disease litigation. Many offer free consultations. They can argue the denial is arbitrary or the plan breached its duty.
• Use patient assistance programs from pharma companies, non-profits, or disease foundations. They may cover treatment costs or provide legal aid.
• Consider a class action if the denial pattern affects many patients. That is a longer-term path.

When Automated Screening Triggers the Denial

Rare disease claims are the kind automated systems flag most often: unusual codes, high costs, no matching guideline. A 2025 National Association of Insurance Commissioners survey of 93 insurers in 16 states found 84% use AI or machine learning across product lines, and 12% of individual major medical insurers reported using it to deny prior authorizations.

A 2025 American Medical Association survey found 61% of physicians worried AI will increase denials of necessary care. A Commonwealth Fund survey found about one in five working-age adults with private insurance reported they or a family member were denied coverage for recommended care in 2025.

The peer-to-peer and external review steps exist to force a human clinician to look at your actual record instead of an algorithm. When you request documents in Step 1, ask whether an automated tool was involved in the decision and what human review, if any, took place. In 2025, many insurers pledged to have medical professionals review prior authorization denials that involve clinical issues; your appeal can hold a plan to that standard.

Key Tips for Employees and Employers

Both sides can reduce friction for rare disease claims:

• Employers: Review your plan's medical necessity criteria for rare diseases during annual enrollment. Consider a "rare disease rider" or work with a TPA experienced in rare conditions. Some self-funded employers include orphan drug provisions to avoid automatic denials.
• Employees: Document everything from day one: medications, visits, denial letters. Get a "plan of care" from your specialist stating the treatment and why it's essential. If enrolled in a health-to-wealth system like WellthCare™ that rewards prevention, note that early documentation can support later appeals. WellthCare's AI-drafted, clinician-reviewed plans of care create a documented, clinically-supported record that strengthens any appeal you may need.

Why Persistence Pays Off

Appeals overturn denials more often than most patients expect. KFF's analysis of ACA marketplace data found insurers overturned roughly 39% to over 60% of internal appeals, depending on the insurer and year. External review decisions overturned the initial denial almost half the time. Treat the appeals process not as a formality but as a rigorous, evidence-based negotiation. Understand the system, build a strong case, use every legal lever available. For employers, a more transparent benefits ecosystem that rewards prevention and reduces waste can prevent these denials altogether.